C
CONTINEUM THERAPEUTICS, INC. CLASS A COMMON STOCK
NASDAQ: CTNM (Contineum Therapeutics, Inc.)
Last update: 10 hours ago9.78
-0.99 (-9.19%)
AIStockmoo Score
| Value 35% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 0.0 |
| Timing 35% | 2.2 |
| AI Technical info | NA |
| Technical Oscillators info | 2.0 |
| Technical Moving Averages info | 2.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| News Mood info | NA |
| Environment | ×0.79 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -23.0% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | 1.9 |
| Final Score | 0.61 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Contineum Therapeutics, Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| CTNM | - | - | - | 1.69 |
| TRML | 1 B | - | - | 4.76 |
| ABEO | - | - | - | 1.04 |
| FTRE | - | - | - | 3.88 |
| DBVT | - | - | - | 4.87 |
| JANX | - | - | - | 0.810 |
Select this tab to load the latest available analysis.
|
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.82% |
| % Held by Institutions | 79.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Longaeva Partners L.P. | 30 Jun 2026 | 812,757 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Nov 2026 | Yahoo Finance |
Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial
CAMBRIDGE, England & SAN DIEGO, November 09, 2026--Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum) (NASDAQ:CTNM), a clinical-stage biopharmaceutical… |
| 03 Nov 2026 | Yahoo Finance |
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
SAN DIEGO, November 03, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its third-quarter… |
| 29 Oct 2026 | Yahoo Finance |
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
SAN DIEGO, October 29, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is… |
| 13 Oct 2026 | Yahoo Finance |
BMY Reports Mixed Phase III Trial Results, Stock Down
Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs. |
| 12 Oct 2026 | Yahoo Finance |
Contineum drops 25% on mixed Bristol Myers IPF data; Stifel keeps Buy rating
Investing.com -- Contineum Therapeutics (NASDAQ:CTNM) shares reversed course and fell 25% in Monday trading, erasing an initial 27% pre-market surge following Bristol Myers Squibb’s (BMY) announcement that its Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary… |
| 12 Oct 2026 | Yahoo Finance |
Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results
Contineum Therapeutics (NASDAQ:CTNM) shares climbed 27% in premarket trading on Monday after Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 clinical trial results for a pulmonary fibrosis treatment targeting the same biological pathway as Contineum’s lead drug candidate. Contineum shares… |
| 12 Oct 2026 | Yahoo Finance |
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
| 12 Oct 2026 | Yahoo Finance |
Bristol Myers Stock Tumbles on ‘Confounding’ Trial Results
Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028… |
| 12 Oct 2026 | Yahoo Finance |
Bristol Myers Reverses Lower Despite Double Phase 3 Win, As A Key Rival Crashes
Bristol Myers Squibb scored two Phase 3 wins on Monday in lung disease and cancer. The stock fell, however. |
| 30 Sep 2026 | Yahoo Finance |
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the drug was to blame. |
| 24 Sep 2026 | Yahoo Finance |
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received the result biotech investors never want to see: one of its partnered drugs missed the primary endpoint of a Phase 2 trial. JNJ-5120/PIPE-307, which Contineum developed and Johnson & Johnson (NYSE:JNJ) is advancing under a global license and… |
| 15 Sep 2026 | Yahoo Finance |
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. CTNM Stock Drops After Phase 2 MOONLIGHT-1… |
| 15 Sep 2026 | Yahoo Finance |
FDA clears first generic radioligand drug; Sionna turns to layoffs
A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise. |
| 15 Sep 2026 | Yahoo Finance |
Sector Update: Healthcare Stocks Ease Late Afternoon
Healthcare stocks were edging lower late Tuesday afternoon, with the NYSE Healthcare Index and the S… |
| 14 Sep 2026 | Yahoo Finance |
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
SAN DIEGO, September 14, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that the… |
| 14 Sep 2026 | Yahoo Finance |
CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
Contineum said that Johnson & Johnson’s (JNJ) mid-stage trial of JNJ-5120, also known as PIPE-307, failed to meet its main goal in major depressive disorder. |
| 25 Aug 2026 | Yahoo Finance |
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
SAN DIEGO, August 25, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is… |
| 17 Aug 2026 | Yahoo Finance |
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making… |
| Show more | ||
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |